Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Reyisa Bughda,Paraskevi Dimou,Astero Klampatsa,Reena R D'Souza
DOI: https://doi.org/10.2147/ITT.S291767
2022-05-25
ImmunoTargets and Therapy
Abstract:Reyisa Bughda, Paraskevi Dimou, Reena R D'Souza, Astero Klampatsa Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK Correspondence: Astero Klampatsa Thoracic Oncology Immunotherapy Group, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK Tel +44 208 722 4090 Email Fibroblast activation protein (FAP) is a membrane protease that is highly expressed by cancer-associated fibroblasts (CAFs). FAP can modulate the tumor microenvironment (TME) by remodeling the extracellular matrix (ECM), and its overexpression on CAFs is associated with poor prognosis in various cancers. The TME is in part accountable for the limited efficacy of chimeric antigen receptor (CAR)-T cell therapy in treatment of solid tumors. Targeting FAP with CAR-T cells is one of the strategies being researched to overcome the challenges in the TME. This review describes the role of FAP in the TME and its potential as a target in CAR-T cell immunotherapy, summarizes the preclinical studies and clinical trials of anti-FAP-CAR-T cells to date, and reviews possible optimizations to augment their cytotoxic efficiency in solid tumors. Keywords: CAR T-cells, immunotherapy, tumor microenvironment, fibroblasts, fibroblast-activating-protein, solid tumors, stroma Cancer immunotherapy is increasingly recognized as the fifth pillar of cancer treatment. As cancer is seen as a distorted version of our normal selves, the use of our own immune system to recognize and target cancer may render it as the closest solution to combatting cancer. Chimeric antigen receptor (CAR)-T cell therapy has stood out as one of the most promising immunotherapies for cancer, following dramatic results in treatment of hematological malignancies. 1 However, research in treatment of solid tumors using CAR-T cell immunotherapies still faces many challenges, the most prominent one being overcoming the hostile tumor microenvironment (TME). The success of CAR-T cells relies on specific tumor antigen recognition within the TME, but given the heterogeneity of mutations that occur within cancer cells, the target antigens can be masked by the TME and reduce the efficacy of CAR-T cell therapy. 2 Targeting non-cancerous cells that modulate the TME is one of the strategies being explored in treatment of solid tumors. Cancer-associated fibroblasts (CAFs) are ideal candidates for this purpose. They are considered to be more genetically stable in the TME. 3–6 Fibroblast activation protein (FAP) is preferentially expressed on CAFs and it is one of the biomarkers used to identify CAFs. 7 This review summarizes the current literature on the role of CAFs in the TME, as well as pre-clinical and clinical studies of FAP targeting CAR-T cells as a solution to overcome the TME restrictions. In 1989, Gross et al. first described a CAR, that enabled T cells to recognize antigens independent of class II major histocompatibility complex (MHC) molecules. They constructed the receptor by replacing the variable (V) antigen recognition domain of T cell receptor with an antibody V domain, as the two shared a high degree of homology. As a result, the re-engineered T cell receptor consisted of antibody-like recognition domain, T cell receptor extracellular constant C domain, transmembrane domain and cytoplasmic domain. It was successfully expressed on T cell surface, and mediated antigen specific target cell killing, having recognized target cells in a non-MHC dependent manner. T cell activation was measured by the release of proinflammatory cytokine interleukin-2 (IL2). 8 The construction of a functional CAR paved the way for ex vivo engineering of cytotoxic T lymphocytes for recognition of tumor or virally infected cells. Three decades later, CAR-T cell therapy has shown remarkable efficacy in targeting of CD19-expressing B cells in hematological malignancies. The first FDA approved CAR-T cell therapy, Kymriah (tisagenlecleucel, CTL019), has achieved 12-month relapse-free survival rates of 55–59% in the treatment of acute lymphoblastic leukemia (ALL). 9 Yescarta (KTE-C19 axicabtagene ciloleucel) was approved shortly after Kymriah to treat diffuse large B-cell lymphoma (DLBCL) (NCT02529813). It achieved overall response rate of 83% and complete response rate of 58% in clinical trial. 10 Tecartus (brexucabtagene autoleucel, KTE-X19) is the latest FDA approved CAR-T cell therapy for the treatment of relapsed or refractory mantle cell lymphoma (MCL) (NCT03761056). Clinical trial showed 87% of patients responded to the therapy, with 62% achieving complete response (NCT02601313). 11 Given the unprecedented success of CAR-T cell therapies in hematological malignancies, there have been worldwide scientific efforts to develop CAR -Abstract Truncated-
English Else